UPDATED: Alkermes slammed as top depression drug fails two PhIIIs

John Carroll

reported this morning that its closely watched ALKS-5461 failed to hit the primary endpoints in the first two of three Phase III studies, slamming the company and the troubled field of depression research with a serious setback.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS